BAP1 and meningioma: Recently, inactivating BAP1 mutations have been linked to significantly reduced time to recurrence in both Grade III rhabdoid and lower grade meningioma with rhabdoid features (26 months versus 116 months, p < 0.001, hazard ratio 12.89) (5, 6).